Page 15 - பார்க்கர் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பார்க்கர் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பார்க்கர் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை Today - Breaking & Trending Today

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.

Ben Matone , Jeff Richardson , Kaneka Eurogentec , Kwadwoa Koram , Walter Reed Army Institute Of Research , Us Department Of Defense , National Cancer Institute , Noguchi Memorial Institute For Medical Research , National Institute Of Allergy , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , International Vaccine Institute , Defense Consortium , Parker Institute For Cancer Immunotherapy , Nuclear Defense , Department Of Defense Do , National Institutes Of Health , Program Executive Office For Chemical , Apollobio Corporation , Vaccines Trial Network , Defense Advanced Research Projects Agency , University Of Pennsylvania , Wistar Institute , Clinical Trial , Noguchi Memorial Institute ,

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Share this article
Share this article
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 is also the first vaccine candidate for Lassa fever to enter human trials. ....

Greater Accra , Ben Matone , Jeff Richardson , Kaneka Eurogentec , Melanie Saville , J Joseph Kim , Kwadwoa Koram , Walter Reed Army Institute Of Research , Us Department Of Defense , National Cancer Institute , Noguchi Memorial Institute For Medical Research , National Institute Of Allergy , Noguchi Medical Center , Plumbline Life Sciences , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , Defense Consortium , Parker Institute For Cancer Immunotherapy , International Vaccine Institute , Nuclear Defense , Department Of Defense Do , National Institutes Of Health , Program Executive Office For Chemical , Apollobio Corporation , Defense Advanced Research Projects Agency , Vaccines Trial Network ,

BioSpace Movers & Shakers, Feb. 19

Published: Feb 19, 2021
By Alex Keown
PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis. ....

United States , United Kingdom , John Hohneker , Tamraj Adams , Paul Kidwell , Ute Dugan , Nawal Ouzrem , Kristi Clark , Joe Johntson , Bridget Okeeffe , Natalie Holles , Bristol Myers Squibb , Jane Salik , Barry Blake , Charles Albright , Alan Boyd , Richard Kim , Don Ross , Burroughs Wellcome , Evelo Biosciences , Matteo Levisetti , Aeglea Biotherapeutics , Gaurav Dave , Wendyk Chung , Los Angeles , Davidp Dimmock ,

Improving Cancer Immunotherapy by Blocking Glucose Supply

Improving Cancer Immunotherapy by Blocking Glucose Supply
Source: Stocktrek Images/Getty Images
February 17, 2021
Share
All cells use sugar as a vital source of energy and building blocks. Unfortunately, that means even cancer cells use sugar. Researchers at Memorial Sloan Kettering (MSK) Cancer Center wondered what happens when tumor cells and immune cells battle for the same sugar supply. Using mouse models and data from human patients, the researchers found a direct relationship between the amount of sugar that a tumor consumes and the effectiveness of immunotherapy. The more sugar the tumor consumed, the less effective the immunotherapy.
Nature and suggest that blocking cancer cells’ use of sugar could tip the scales in favor of immune cells, especially when they are activated by immunotherapy drugs. ....

Taha Merghoub , Roberta Zappasodi , Ludwig Center , Cancer Center , Parker Institute For Cancer Immunotherapy , Memorial Sloan Kettering , Parker Institute , Parker Institute Bridge , Weill Cornell , லுட்விக் மையம் , புற்றுநோய் மையம் , பார்க்கர் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை , நினைவகம் ஸ்லோன் கெட்டரிங் , பார்க்கர் நிறுவனம் , பார்க்கர் நிறுவனம் பாலம் , வெயில் கார்னெல் ,

Suppressive immune cells' metabolic vulnerability may be targeted for cancer immunotherapy

E-Mail
IMAGE: Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi
view more
Credit: Ludwig Cancer Research
FEBRUARY 15, 2021, NEW YORK - A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis.
Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi now at Weill Cornell Medicine have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system. In such tumors, anti-CTLA-4 therapy also destabilizes and reprog ....

United States , Taha Merghoub , Roberta Zappasodi , Breast Cancer Research Foundation , Us National Cancer Institute , Weill Cornell Medical College , A Ludwig Cancer Research , Ludwig Cancer Research , Ludwig Center , Ludwig Collaborative Swim Across America Laboratory , Swiss National Science Foundation , Parker Institute For Cancer Immunotherapy , European Research Council , Jedd Wolchok , Memorial Sloan Kettering Cancer Center , Roberta Zappasodi Now , Weill Cornell Medicine Have , Swim Across America , Parker Institute , Cancer Institute , European Research , Ludwig Collaborative , Swim Across America Laboratory , Weill Cornell Medical , Weill Cornell , Medicine Health ,